Aeglea Bio Therapeutics Reports P-I/II Clinical Trial Results of Pegtarviliase for the Treatment of Classical Homocystinuria
Shots:
- The company highlighted the interim results from an ongoing P-I/II trial evaluating pegtarviliase in patients with Classical Homocystinuria
- The results from the first two cohorts (0.15 & 0.45mg/kg) lowered total homocysteine levels over baseline values. The third cohort's results (1.35 mg/kg) did not demonstrate a consistent decline in total homocysteine levels from baseline, participants developed ADAs
- The therapy was well tolerated, 1 serious AEs assessed as unrelated to treatment & no patients withdrew from the trial or had a dose reduction due to AEs, and percent change of total homocysteine from baseline after 4wks. of treatment in 1/2/3 cohort (-26.3%/-33.0%/-11.3%) at 3 days post-dose; -8.0%/ -26.8%/ +15.0% at 7 days post-dose
Ref: PR Newswire | Image: Aeglea
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
